Press release
Deadline on September 26th coming up in Lawsuit for Investors in Enochian Biosciences, Inc. (NASDAQ: ENOB)
A Deadline is coming up on September 26, 2022 in the lawsuit for certain investors in Enochian Biosciences, Inc. (NASDAQ: ENOB).
Investors who purchased shares of Enochian Biosciences, Inc. (NASDAQ: ENOB) have certain options and there are strict and short deadlines running. Deadline: September 26, 2022. NASDAQ: ENOB stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Central District of California the plaintiff alleges on behalf of purchasers of Enochian Biosciences, Inc. (NASDAQ: ENOB) common shares between September 24, 2020 and May 31, 2022, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between September 24, 2020 and May 31, 2022, the Defendants made false and/or misleading statements and/or failed to disclose thatGumrukcu was not a licensed doctor and had no verifiable degrees beyond high school, that accordingly, the scientific and technological underpinnings of Enochian's product pipeline, purportedly invented by Gumrukcu, were dubious at best, that accordingly, the Defendants had significantly overstated the commercial prospects for the Company's product pipeline, that Enochian's senior leadership knew Gumrukcu had a criminal history that included fraud, that accordingly, Enochian's reliance on Gumrukcu, and its consulting and licensing agreements with G-Tech and SRI, subjected the Company to a heightened risk of reputational and financial harm, as well as threatened the integrity of the Company's scientific findings, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Enochian Biosciences, Inc. (NASDAQ: ENOB) have certain options and should contact the Shareholders Foundation.
Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on September 26th coming up in Lawsuit for Investors in Enochian Biosciences, Inc. (NASDAQ: ENOB) here
News-ID: 2740472 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for Enochian
Lawsuit filed for Investors in shares of Enochian Biosciences, Inc. (NASDAQ: ENO …
An investor, who purchased shares of Enochian Biosciences, Inc. (NASDAQ: ENOB), filed a lawsuit over alleged violations of Federal Securities Laws by Enochian Biosciences, Inc.
Investors who purchased shares of Enochian Biosciences, Inc. (NASDAQ: ENOB) have certain options and for certain investors are short and strict deadlines running. Deadline: September 26, 2022. NASDAQ: ENOB investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Los Angeles, CA based…
Investigation announced for Investors in Enochian Biosciences, Inc. (NASDAQ: ENO …
An investigation was announced over potential securities laws violations by Enochian Biosciences, Inc. in connection with certain financial statements.
Investors who purchased shares of Enochian Biosciences, Inc. (NASDAQ: ENOB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Enochian Biosciences, Inc. regarding its business, its prospects and its operations were…
Gamma Delta T Cell Cancer Therapy Market and Clinical Trials Forecast 2028
"Gamma Delta T Cell Cancer Therapy Market and Clinical Trials Forecast 2028" Report Highlights:
* Commercialization Market Potential After Market Launch: > USD 4 Billion
* Insight on Key Drugs In Research and Development
* Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight
* Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies
* Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type
* Adopted Approaches for Gamma Delta…
Dendritic Cell and Tumor Cell Cancer Vaccine Market is Thriving Worldwide with T …
Dendritic Cell and Tumor Cell Cancer Vaccine market Research Report
LOS ANGELES, United States: QY Research offers an overarching research and analysis-based study on, “Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Report, History and Forecast 2016-2027, Breakdown Data by Manufacturers, Key Regions, Types and Application“. This report offers an insightful take on the drivers and restraints present in the market. Dendritic Cell and Tumor Cell Cancer Vaccine data…
Global Dendritic Cell Cancer Vaccine Market is expected to grow at a substantial …
Overview:
Dendritic cells (DCs) are antigen-presenting cells that assist in the body's immune response initiation and regulation. Abnormal proliferating cells marked by different surface antigens are cancer cells. For cancer immunotherapy, dendritic cells are used to identify a cancer cell and then start the phagocytosis process against those targeted cancer cells. In nature, dendritic cells are adaptable. Dendritic cell vaccines became one of the most promising approaches as it works by…
Dendritic Cell and Tumor Cell Cancer Vaccine Market Trends Analysis, Top Manufac …
Complete study of the global Dendritic Cell and Tumor Cell Cancer Vaccine market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Dendritic Cell and Tumor Cell Cancer Vaccine industry. Research techniques like PESTLE and Porter's Five Forces…
